178 related articles for article (PubMed ID: 2285304)
1. Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin.
Chaudhry AZ; Knapp CC; Sierra-Madero J; Washington JA
Antimicrob Agents Chemother; 1990 Sep; 34(9):1843-5. PubMed ID: 2285304
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
Smith KR; Cobbs CG
Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):55-8. PubMed ID: 1314175
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.
Rotstein C; Amsterdam D; Beam TR; Mandell LA; Gorzynski EA
Diagn Microbiol Infect Dis; 1993 Jul; 17(1):85-91. PubMed ID: 8395375
[TBL] [Abstract][Full Text] [Related]
4. Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin.
Barry AL; Fuchs PC
Eur J Clin Microbiol Infect Dis; 1991 Mar; 10(3):168-71. PubMed ID: 2060518
[TBL] [Abstract][Full Text] [Related]
5. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
6. In-vitro slime production by Staphylococcus epidermidis in presence of subinhibitory concentrations of ciprofloxacin, ofloxacin and sparfloxacin.
Pérez-Giraldo C; Rodríguez-Benito A; Morán FJ; Hurtado C; Blanco MT; Gómez-García AC
J Antimicrob Chemother; 1994 Apr; 33(4):845-8. PubMed ID: 8056703
[No Abstract] [Full Text] [Related]
7. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Malmborg AS; Ahlén S
Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
[TBL] [Abstract][Full Text] [Related]
8. Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin.
Drugeon HB; Juvin ME; Bryskier A
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():55-9. PubMed ID: 10404339
[TBL] [Abstract][Full Text] [Related]
9. Improved bactericidal activity of Q-35 against quinolone-resistant staphylococci.
Ito T; Matsumoto M; Nishino T
Antimicrob Agents Chemother; 1995 Jul; 39(7):1522-5. PubMed ID: 7492097
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of sparfloxacin.
Chin NX; Gu JW; Yu KW; Zhang YX; Neu HC
Antimicrob Agents Chemother; 1991 Mar; 35(3):567-71. PubMed ID: 2039209
[TBL] [Abstract][Full Text] [Related]
11. Activity of new quinolones against ciprofloxacin-resistant staphylococci.
Forstall GJ; Knapp CC; Washington JA
Antimicrob Agents Chemother; 1991 Aug; 35(8):1679-81. PubMed ID: 1656873
[TBL] [Abstract][Full Text] [Related]
12. Antistaphylococcal and antistreptococcal killing kinetics of ciprofloxacin, ofloxacin, sparfloxacin, and trovafloxacin.
Prenna M; Montanari MP; Mingoia M; Biavasco F; Ripa S; Varaldo PE
Eur J Clin Microbiol Infect Dis; 1998 Nov; 17(11):816-9. PubMed ID: 9923533
[No Abstract] [Full Text] [Related]
13. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.
Schmitz FJ; Hofmann B; Hansen B; Scheuring S; Lückefahr M; Klootwijk M; Verhoef J; Fluit A; Heinz HP; Köhrer K; Jones ME
J Antimicrob Chemother; 1998 Apr; 41(4):481-4. PubMed ID: 9598779
[TBL] [Abstract][Full Text] [Related]
14. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.
Jones ME; Visser MR; Klootwijk M; Heisig P; Verhoef J; Schmitz FJ
Antimicrob Agents Chemother; 1999 Feb; 43(2):421-3. PubMed ID: 9925551
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin.
Rastogi N; Goh KS
Antimicrob Agents Chemother; 1991 Sep; 35(9):1933-6. PubMed ID: 1952872
[TBL] [Abstract][Full Text] [Related]
16. In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.
Jones RN; Barrett MS; Erwin ME; Briggs BM; Johnson DM
Diagn Microbiol Infect Dis; 1991; 14(4):319-30. PubMed ID: 1909615
[TBL] [Abstract][Full Text] [Related]
17. In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
Kim JH; Choi KH; Kim JW; Lee JH; Choi EC; Kim BK
J Antimicrob Chemother; 1998 Feb; 41(2):223-9. PubMed ID: 9533464
[TBL] [Abstract][Full Text] [Related]
18. The bactericidal activity of levofloxacin against ampicillin-resistant and ampicillin-susceptible Haemophilus influenzae in comparison with ofloxacin, ciprofloxacin and sparfloxacin.
Dabernat H
Int J Antimicrob Agents; 1999 Feb; 11(2):139-43. PubMed ID: 10221417
[TBL] [Abstract][Full Text] [Related]
19. Activity of gatifloxacin against strains resistant to ofloxacin and ciprofloxacin and its ability to select for less susceptible bacterial variants.
Fung-Tomc J; Gradelski E; Huczko E; Minassian B; Bonner DP
Int J Antimicrob Agents; 2001 Jul; 18(1):77-80. PubMed ID: 11463531
[TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
